arrow
R

Ronald S. Go

Mayo Clinic
H指数:72
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the Efficacy of Cytokine-Directed Therapies in the Management of VEXAS Syndrome

评估细胞因子导向疗法在VEXAS综合征管理中的疗效

2026-09-250
OAAI
Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival

1q染色体增益定义了AL淀粉样变性中一种浆细胞占优势的不良风险亚型,其长期生存率较差

2026-08-260
PRE
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients

达雷木单抗治疗的新诊断多发性骨髓瘤患者中缺铁的高发生率

2026-08-210
PRE
Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma
Leukemia
IF13.4
2026-07-210
PRE
Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

达拉妥单抗、伊沙佐米和来那度胺联合或不联合地塞米松治疗新诊断骨髓瘤的初始疗法

2026-07-180
OA
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

自体干细胞移植治疗多发性骨髓瘤后继发血液系统恶性肿瘤的特征与结局

2026-06-230
OAAI
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia

原发性浆细胞白血病患者首次进展后的进展模式与临床结局

2026-06-030
PRE
Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

ALK抑制停止后ALK阳性组织细胞增多症的持续缓解

2026-04-140
OAAI
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and Sales

三十年美国经典血液学药物:批准、成本与销售

2026-03-280
OAAI
Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia

t(11;14)初发细胞遗传学异常及诊断时多种高危细胞遗传学累积效应对原发性浆细胞白血病预后的影响

2025-12-270
OAAI
Longitudinal changes in haemoglobin, iron stores, and inflammatory markers following surgery and in critical illness: an analysis from the Practical Anaemia Bundle for Sustained Blood Recovery randomised clinical trial

手术及危重疾病后血红蛋白、铁储备和炎症标志物的纵向变化:一项来自《Practical Anaemia Bundle for Sustained Blood Recovery》随机临床试验的分析

2025-12-080
PRE